Verastem, Inc. reported a net loss of $36.6 million for the first quarter of 2026, a 30% improvement compared to a net loss of $52.1 million in the same period of the previous year. The company generated $18.7 million in product revenue from its marketed product, AVMAPKI FAKZYNJA CO-PACK, which was launched in May 2025 following FDA approval. This marks the first revenue reported by the company, as it had no product revenue in the first quarter of 2025. Operating expenses for the quarter totaled $63.6 million, up 44% from $44.2 million in the prior year, driven primarily by increased research and development costs and selling, general, and administrative expenses.
The increase in operating expenses was largely attributed to a 31% rise in research and development costs, which reached $38.2 million, compared to $29.2 million in the previous year. This increase was due to higher investigator fees, drug manufacturing costs, and clinical supply expenses. Selling, general, and administrative expenses also rose by 48% to $22.3 million, reflecting increased personnel costs and commercial operations expenses. The company’s total cash, cash equivalents, and investments stood at $181.7 million as of March 31, 2026, down from $205.2 million at the end of 2025.
Verastem's operational developments include the ongoing international Phase 3 trial, RAMP 301, which is evaluating the effectiveness of AVMAPKI FAKZYNJA CO-PACK in recurrent low-grade serous ovarian cancer. The company also announced new data from the Phase 2 RAMP 201 trial, demonstrating durable benefits of the drug combination across various patient groups. Additionally, Verastem is advancing its pipeline with VS-7375, a selective oral KRAS G12D dual ON/OFF inhibitor, which is currently in a Phase 1/2 clinical trial.
The company has expressed concerns regarding its ability to continue as a going concern, citing the substantial increase in projected research and development expenses due to the initiation of new clinical trials. Verastem plans to finance its operations through existing cash reserves, potential future product revenues, and strategic financing opportunities, although it acknowledges the risks associated with these potential funding sources. The company is actively seeking to expand its market presence and product offerings while navigating the challenges of clinical development and commercialization.
About Verastem, Inc.
Verastem, Inc. is a biopharmaceutical company focused on developing and commercializing targeted small molecule therapies for RAS/MAPK pathway-driven cancers. Its pipeline includes RAF/MEK inhibitors, FAK inhibitors, and KRAS inhibitors, targeting solid tumors such as ovarian, lung, and pancreatic cancers. The company emphasizes innovative mechanisms, strategic partnerships, and regulatory pathways to improve treatment outcomes for patients with difficult-to-treat cancers.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.